Lindbrook Capital, LLC Pacira Bio Sciences, Inc. Transaction History
Lindbrook Capital, LLC
- $1.09 Billion
- Q4 2024
A detailed history of Lindbrook Capital, LLC transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Lindbrook Capital, LLC holds 531 shares of PCRX stock, worth $12,770. This represents 0.0% of its overall portfolio holdings.
Number of Shares
531
Previous 118
350.0%
Holding current value
$12,770
Previous $1,000
900.0%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding PCRX
# of Institutions
260Shares Held
49.8MCall Options Held
1.03MPut Options Held
139K-
Black Rock Inc. New York, NY8.01MShares$193 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.26MShares$127 Million0.0% of portfolio
-
Pacer Advisors, Inc. Malvern, PA3.26MShares$78.5 Million0.15% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY2.26MShares$54.3 Million0.03% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.99MShares$47.9 Million0.06% of portfolio
About Pacira BioSciences, Inc.
- Ticker PCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 45,824,200
- Market Cap $1.1B
- Description
- Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...